Status:
UNKNOWN
Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborating Sponsors:
Max Planck Institute for Infection Biology
Meir Hospital, Kfar Saba, Israel
Conditions:
Childhood Cancer
Eligibility:
All Genders
Up to 21 years
Brief Summary
Identifying the post-transplantation phase wherein neutrophils recover their ability to release NETs could shed new light on the mechanism responsible for the increased susceptibility to infection amo...
Detailed Description
Although neutrophil engraftment takes place 10 to 14 days after autologous HSCT, and 15 to 30 days after allogeneic HSCT, using an ablative conditioning regimen, neutrophil dysfunction may persist for...
Eligibility Criteria
Inclusion
- All infants, children and adolescents undergoing autologous and allogeneic HSCT at the pediatric hemato-oncology departement of Dana children's Hospital.
Exclusion
- Severe background diseases (like diabetes and lupus) that there is no data in the literature on their influence on NETs production.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01491230
Start Date
December 1 2011
End Date
December 1 2014
Last Update
December 13 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Children's Hospital, Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239